Anthony B. Evnin, Director at Juno Therapeutics, Inc. (JUNO), sold 583,333 shares at $51.59 ($30.8M) on 2015-06-17, disclosed to the SEC on 2015-06-19.
Scheduled sale ($30.8M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $51.59 | 90,141 | $4.7M | 15.1% |
| 2 | $52.65 | 94,080 | $5.0M | 16.1% |
| 3 | $53.84 | 63,574 | $3.4M | 11.1% |
| 4 | $54.70 | 28,603 | $1.6M | 5.1% |
| 5 | $55.85 | 11,602 | $648K | 2.1% |
| 6 | $56.32 | 12,000 |
| $676K |
| 2.2% |
| 7 | $52.07 | 78,569 | $4.1M | 13.3% |
| 8 | $52.74 | 154,495 | $8.1M | 26.4% |
| 9 | $53.58 | 50,269 | $2.7M | 8.7% |
| Total | $52.88 avg | 583,333 | $30.8M | 100% |
| Filing → |
| CNST | BUY | 2019-10-04 | $48.0M | — | Filing → |
| AVEO | BUY | 2018-11-26 | $223 | — | Filing → |
| AVEO | SELL | 2018-11-16 | $4.3M | — | Filing → |